Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Decision Resources
August 27, 2009 22 Pages - SKU: DECR2427948
|
|
Introduction
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial
revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as
Novartis's Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML
patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on
the unmet needs of current therapeutics have a good chance of replicating Gleevec's success.
Questions Answered in This Report
- Properly diagnosing CML is an integral part of choosing an effective treatment. How is CML diagnosed?
What role does genetic testing play in developing and deploying drugs for CML? What are the
symptoms of CML?
- Treatment options for CML are more targeted today than in recent history. How was CML previously
treated? Why have targeted therapies proved to be better CML treatment options?
- Despite treatment advances, opportunities remain for emerging CML agents. What are these
opportunities? Are the opportunities potentially lucrative enough to motivate drug developers?
Scope
- Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis,
classification, epidemiology, and disease progression.
- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
- Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.
- Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Disease Overview
- Etiology and Pathophysiology
- BCR-ABL-Positive Patients
- BCR-ABL-Negative Patients
- Diagnosis and Classification
- Patient Population, Symptoms, and Disease Progression
- Current Therapies
- Drug Therapies
- Novartis’s Gleevec
- Novartis’s Tasigna
- Bristol-Myers Squibb’s Sprycel
- Interferon-Alpha
- Generic Chemotherapeutic Agents
- Progenitor Stem Cell Transplantation
- Myeloablative Regimens
- Allogenic Progenitor Stem Cell Transplantation
- Autologous Progenitor Stem Cell Transplantation
- Emerging Therapies
- Wyeth’s Bosutinib (SKI-606)
- Novartis’s Panobinostat (LBH-589)
- ChemGenex Pharmaceuticals’ Omacetaxine Mepesuccinate
- 2008 Statistics and Market Outlook
- Tables
- 1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia
- 2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia
- 3. Commonly Used Current Therapies in the Treatment of Chronic Myelogenous Leukemia
- 4. Emerging Therapies for Chronic Myelogenous Leukemia
- 5. 2008 Worldwide Chronic Myelogenous Leukemia Market
- Figures
- 1. The Philadelphia-Chromosome
- 2. Prevalent, Diagnosed Cases of Chronic Myelogenous Leukemia in the Major Pharmaceutical Markets, 2008 and 2013
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
